Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151375 | 0.89 | CNR1 (0.32) | CNR1ALDH1A1SMN1; SMN2TACR1LMNA | |
| SCHEMBL6725314 | 0.87 | CNR1 (0.43) | CNR1ALDH1A1SMN1; SMN2TACR1LMNA | |
| SCHEMBL6728550 | 0.87 | CNR1 (0.43) | CNR1ALDH1A1SMN1; SMN2TACR1LMNA | |
| SCHEMBL14519637 | 0.84 | CNR1 (0.45) | CNR1ALDH1A1SMN1; SMN2TACR1LMNA | |
| SCHEMBL11482548 | 0.82 | ALDH1A1 (0.43) | CNR1ALDH1A1SMN1; SMN2TACR1LMNA | |
| SCHEMBL11091144 | 0.80 | CNR1 (0.49) | CNR1ALDH1A1TACR1 | |
| SCHEMBL11484816 | 0.79 | CNR1 (0.48) | CNR1ALDH1A1SMN1; SMN2TACR1 | |
| SCHEMBL11488928 | 0.79 | CNR1 (0.48) | CNR1ALDH1A1SMN1; SMN2TACR1 | |
| SCHEMBL7699126 | 0.79 | CNR1 (0.48) | CNR1ALDH1A1SMN1; SMN2TACR1 | |
| SCHEMBL11490607 | 0.78 | CNR1 (0.47) | CNR1ALDH1A1SMN1; SMN2TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045480-B2 | Sterically hindered amine light stabilizers | BASF SE (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045480-B2 | Sterically hindered amine light stabilizers | BASF SE (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20120108709-A1 | NOVEL STERICALLY HINDERED AMINE LIGHT STABILIZERS | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010142576-A1 | NOVEL STERICALLY HINDERED AMINE LIGHT STABILIZERS | BASF SE (DE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108709-A1 | NOVEL STERICALLY HINDERED AMINE LIGHT STABILIZERS | AAAS, CRY1, TAAR1 | CNR1 1039/4885ALDH1A1 390/4885SMN1; SMN2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.